A proteomic landscape of diffuse-type gastric cancer

Area of Science:

• Oncology
• Proteomics
• Genomics

Background:

• Diffuse-type gastric cancer (DGC) presents a poor prognosis and limited therapeutic strategies.
• Understanding the molecular heterogeneity of DGC is crucial for developing targeted treatments.

Purpose of the Study:

• To present a comprehensive dataset of proteomic and mutation information from DGC patients.
• To identify molecular subtypes within DGC and nominate potential therapeutic vulnerabilities and immunotherapy targets.

Main Methods:

• Proteomic analysis of 11,340 gene products and mutation data for 274 cancer driver genes from 84 DGC patients (paired tumor and nearby tissue).
• Bioinformatic analysis to classify DGC into subtypes based on proteomic alterations.
• Identification of potential therapeutic targets and immunotherapy candidates.

Main Results:

• DGC was classified into three subtypes (PX1-3) based on proteomic profiles.
• PX1 and PX2 subtypes showed cell cycle dysregulation, with PX2 additionally exhibiting epithelial-mesenchymal transition (EMT).
• The PX3 subtype, enriched in immune response proteins, demonstrated the poorest survival and chemoresistance, highlighting it as a key target for immunotherapy.

Conclusions:

• Proteomic analysis enables robust molecular subtyping of DGC, revealing distinct patient subgroups.
• The study identified four major vulnerabilities in DGC and nominated specific immunotherapy targets, especially for the PX3 subtype.
• This dataset serves as a valuable resource for further research into DGC signaling pathways and personalized treatment strategies.